Results 11 to 20 of about 305 (130)
CNS Neuroscience and Therapeutics, 2008 For almost three decades ambroxol has been used in the therapy of airway diseases. In 2002, ambroxol lozenges were marketed for the treatment of sore throat making use of its local anesthetic effect. Detailed investigations of ambroxol with modern pharmacological methods yielded additional interesting results: ambroxol has been found to have profound ...
exaly +3 more sources
Frontiers in Microbiology, 2022 Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its ...
Yun Lu +13 more
doaj +1 more source
Pharmaceutical Sciences and Research, 2023 Ambroxol HCl is a mucolytic agent often used to treat respiratory disorders associated with excess mucus secretion. This study aims to determine the beyond-use date (BUD) of ambroxol HCl syrup on the market based on analysis of the decrease in drug ...
Catur Jatmika +2 more
doaj +1 more source
Фармацевтичний журнал, 2020 The determination of the qualitative and quantitative content of the main active substance of a microlitic medicinal product is necessary to confirm its good quality.
І. V. Nigencovska +3 more
doaj +1 more source
Ambroxol: A potential therapeutics against neurodegeneration
Health Sciences Review, 2023 Ambroxol hydrochloride is a pharmacological chaperone approved by FDA as an expectorant. Currently, it is used as an antitussive and anti-asthmatic agent.
Prajwal Dhanve +4 more
doaj +1 more source
Rational mucolytic therapy with ambroxol: controversial and indisputable. A review
Consilium Medicum, 2023 Many years of experience in the use of ambroxol is based on its ability to regulate the basic mechanisms of physiological production and transport of bronchial mucus.
Sergey L. Babak +2 more
doaj +1 more source
Ambroxol therapy for Parkinson’s disease: Systematic literature review [PDF]
Romanian Journal of Neurology, 2023 Parkinson’s disease (PD) is the second most common neurodegenerative disease. The accumulation of α-synuclein protein in the basal ganglia is the underlying pathogenesis of PD. Genetic abnormalities are one of the predisposing factors for PD.
Virgi Mayang Maharani +3 more
doaj +1 more source
Beneficial effects of ambroxol hydrochloride on pentylenetetrazol-induced convulsion model in rats
Medicine Science, 2020 In present experimental study, we purposed to research if ambroxol would have beneficial acute effects on PTZ-induced convulsions by EEG records. 48 rats were randomly divided into two groups; group A for EEG recordings and B for behavioral evaluations ...
Eda Sunnetci +3 more
doaj +1 more source
PERBANDINGAN MUTU FISIK TABLET AMBROXOL MEREK DAGANG X DANTABLETMBROXOL GENERIK
Jurnal Farmasi Sains dan Praktis, 2018 Ambroxol adalah salah satu obat yang masuk kedalam golongan mukolitik. Dimana tujuan dari penelitian ini adalah mengetahui perbandingan mutu fisik tablet Ambroxol merek dagang dan tablet Ambroxol generik.
oktavia friski +2 more
doaj +1 more source
Molecular Genetics and Metabolism Reports, 2020 Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the acid β-glucosidase encoding gene (GBA1), resulting in the deficient activity of acid β-glucosidase (GCase).
Giovanni Ciana +10 more
doaj +1 more source